Clinical Trial Update: Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia [Phase 2]

View source ↗

Summary

This Phase 2 trial compares pacritinib to hydroxyurea in advanced proliferative chronic myelomonocytic leukemia and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelomonocytic Leukemia

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Pacritinib (pacritinib)

Snippet

Sponsor: Theradex | Conditions: Leukemia, Myelomonocytic, Chronic | Phase 2 | Status: RECRUITING